ImmuCell (NASDAQ:ICCC) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?
by Kim Johansen · The Markets DailyImmuCell Corporation (NASDAQ:ICCC – Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $6.95 and traded as high as $9.80. ImmuCell shares last traded at $9.77, with a volume of 17,969 shares traded.
Analysts Set New Price Targets
Separately, Weiss Ratings downgraded shares of ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a report on Monday, April 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.
Check Out Our Latest Stock Report on ImmuCell
ImmuCell Stock Performance
The firm has a market capitalization of $88.15 million, a price-to-earnings ratio of -162.31 and a beta of 0.55. The stock’s fifty day moving average is $8.61 and its two-hundred day moving average is $7.02. The company has a quick ratio of 2.60, a current ratio of 4.82 and a debt-to-equity ratio of 0.24.
ImmuCell (NASDAQ:ICCC – Get Free Report) last issued its earnings results on Thursday, May 14th. The biotechnology company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.16. The business had revenue of $10.36 million for the quarter, compared to the consensus estimate of $5.40 million. ImmuCell had a negative net margin of 1.82% and a negative return on equity of 1.88%.
Hedge Funds Weigh In On ImmuCell
Institutional investors and hedge funds have recently modified their holdings of the stock. Militia Capital Management LLC acquired a new position in shares of ImmuCell in the first quarter valued at $114,000. Steadtrust LLC acquired a new position in shares of ImmuCell in the third quarter valued at $198,000. Mesirow Financial Investment Management Inc. increased its holdings in shares of ImmuCell by 199.6% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after purchasing an additional 24,303 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of ImmuCell by 3.2% in the first quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 1,749 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of ImmuCell by 4.2% in the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after purchasing an additional 2,907 shares during the last quarter. 13.47% of the stock is currently owned by institutional investors and hedge funds.
ImmuCell Company Profile
ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.
The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.